Standard clinical practice recommends minimal doses of vasoactive drugs during weaning of patients from mechanical ventilation. However, there are currently no clinical data to inform clinicians about whether the use of noradrenaline during weaning predisposes to weaning failure. The objective of this study was to evaluate whether the necessity of the vasopressor noradrenaline in mechanically ventilated patients recovering from septic shock changed the extubation outcome.
Weaning from mechanical ventilation (MV) is the process of reducing mechanical ventilatory support and may represent up to 40% of the time spent by patients on MV 1,2 optimal time for extubation because prolonged MV increases the risk of nosocomial pneumonia, airway trauma, bleeding from stress ulcers and mortality 1, [3] [4] [5] [6] . Successful weaning and extubation depends on many factors including patient recovery from the acute phase of disease, adequate oxygenation and ventilatory parameters, a stable cardiovascular system without myocardial ischaemia or dependence on vasopressor drugs, an effective cough, normal acid-basic status and electrolytes 1, [7] [8] [9] . Oxygen consumption by respiratory muscles is increased during weaning from MV. It is possible that vasoactive drugs used during weaning could divert blood to vital organs rather than skeletal muscles, increasing the rate of extubation and weaning failure [10] [11] [12] . Standard clinical practice therefore recommends discontinuation of vasoactive drug treatment before weaning starts. Our experience, however, suggests that in practice, this can prolong the time spent in MV unnecessarily. Furthermore, a Medline search using the search terms: mechanical ventilation, weaning, vasoactive drugs and noradrenaline (1969 to 2005) did not retrieve any clinical studies that have investigated this issue. The objective of this study is to evaluate if the necessity of the vasopressor noradrenaline in mechanically ventilated patients recovering from septic shock, change the extubation outcome.
MATERIALS AND METHODS
This study was conducted between January of 2005 and September of 2005 in two medical-surgical intensive care units (ICU) in the Moinhos de Vento Hospital and Central ICU at Santa Casa Hospital (Porto Alegre, Brazil). The study was approved by the Ethics in Research Committee of both hospitals. Informed consent was presented and agreed by the patients' families.
We included consecutive septic patients receiving mechanical ventilatory support for more than 48 hours with the Servo 900C ® ventilator (Siemens-Elema AB, Sweden) or Evita-4 ® ventilator (Dräger Medical Systems Inc, U.S.A.) and extubated using low to moderate doses of noradrenaline 10 Exclusion criteria were non-septic patients, septic patients using any vasopressor other than noradrenaline, ratio of respiratory rate to tidal volume (f/V T 2 O, and failure to tolerate a spontaneous breathing trial (SBT) ( Figure 1 ).
All patients in the noradrenaline group were haemodynamically stable and received stable noradrenaline doses during the last 24 hours before weaning. None of the patients tolerated the suspension of noradrenaline in the 24 hours preceding SBT based on a mean arterial pressure <60 mmHg, drop in urinary output to <0.5 ml/kg/h or drowsiness, coma and acute agitation during noradrenaline suspension trial. The study protocol did not allow the noradrenaline dose to change during the SBT. The control group consisted of septic patients with the same characteristics as the noradrenaline group, but receiving no vasopressor drugs at the time of weaning ( Table 1) .
After interruption of MV support, patients and as much oxygen as necessary to achieve an oximetry. 13 , MIP, MV days, arterial gases, vital signs and the outcomes of reintubation and death in the ICU.
Statistical analysis
Results are given as mean ± SD or as a percentage. All categorical variables were analysed with chi-square test or Fisher's exact test for small 14 .
RESULTS
from septic shock were enrolled during nine months; 63 patients in the noradrenaline group and 82 patients in the control group. There were no major differences in baseline characteristics between groups (Table 1) . During the weaning trial, all blood gas values, ventilatory and haemodynamic parameters were compatible with an extubation attempt according to weaning guidelines, and did not differ between extubation success and extubation failure groups ( Table 2 ). The noradrenaline dose during the septic shock treatment was similar in extubation failure and extubation success patients ( Figure 2 and Table 2 ). In the noradrenaline group, the maximal noradrenaline dose was 0.52±0.29 μg/kg/min in the initial shock treatment and 0.12±0.10 μg/kg/min on the day of SBT. There were no differences in rates of reintubation (noradrenaline: 12/63, 19% vs. control: 15/82, 18.3%, P=1.00) or mortality (noradrenaline: 10/63, 15.9% vs. control: 11/82, 13.4%, P=0.81) between groups.
DISCUSSION
In this two-centre observational study, we did noradrenaline (<0.2 μg/kg/min) on the success of weaning and extubation among mechanically ventilated septic patients. This study suggests that patients can be weaned and extubated while exposed to noradrenaline without increasing the risk of extubation failure in patients who successfully tolerate a SBT. Previous weaning studies have not examined this question because they excluded patients receiving vasoactive agents or included only patients using small doses of dopamine or dobutamine 1,5,7-9 .
Although noradrenaline is frequently used in ICUs (noradrenaline was the vasopressor used to treat 86% of septic shock patients in the ICUs enrolled in this nine-month study), noradrenaline is not cited in the medical literature or weaning guidelines 1 . Noradrenaline is a potent -receptor agonist and has relatively little action on ß-receptors 10 . Its infusion in humans causes increased blood pressure while cardiac output is maintained or even reduced; increased peripheral vascular resistance in most vascular beds; reduced muscles 11 . Noradrenaline increases oxygen delivery less than it increases oxygen uptake and may decrease regional perfusion 11, 12 . The process of discontinuation from MV may increase breathing effort and also load to the cardiovascular system 1, [15] [16] [17] [18] [19] . Therefore, the use of noradrenaline at the time of SBT could divert blood to the vital organs and deprive skeletal 11, 12 . In theory, this is a reasonable assumption and is a legitimate rationale for current weaning guidelines to suggest the reduction or suspension of vasopressor medication prior to starting withdrawal from MV. However, we found no clinical evidence to support this practice.
The increase in O 2 tissue extraction during weaning trials was elegantly demonstrated by Jubran et al 11 . In this study, the mixed venous saturation (SvO 2 ) fell during SBT in weaning failure patients and did not in weaning success patients, due to an increase in cardiac index in the weaning success group. In a recent study we found that decreased central venous saturation (ScvO 2 ) to be a good weaning failure predictor 20 . Our results agree with the association between MV discontinuation and increased VO 2 , and suggest that it could be related to systemic hypoperfusion in unstable patients.
There are many conditions that could contribute to blood pressure lowering and therefore the necessity of vasopressor use in such patients. Studies of cardiopulmonary interactions indicate that positive pressure ventilation reduces the cardiac output and systemic arterial pressure, mainly in COPD and hypovolaemic patients 21 . Sedative and analgesic drugs used during MV for patient comfort, safety, and ventilatory synchrony, can also lead to hypotension 22 . Some evidence that weaning outcome has been described [23] [24] [25] and the use of diuretic therapy at this time can also cause hypotension. This is an important issue to consider to maximise the success of weaning, because septic patients usually receive large volume resuscitation on arrival at the emergency department or in the ICU, based in "early goal approach" 26 . In our study, the suspension of vasopressor use in the control group occurred 3±2.3 days before weaning and in the noradrenaline group it was suspended six to 12 hours after extubation. In our opinion, the septic process was not the main cause of vasoactive dependency at the time of weaning. the extubation failure group was not surprising since it is known that higher respiratory rates predict a higher risk of weaning failure 1 . Overall, 18.6% of patients were reinubated, but the reintubation rate was similar to that reported in previously published studies [7] [8] [9] . Extubation failure was not statistically different between groups (19% noradrenaline group vs. 18.3% control group); neither was mortality rate (15.9% noradrenaline group vs. 13.4% control group).
Limitations to this study include the observational design; we did not randomise patients to noradrenaline. The sample size is not large, but this test adrenal function in all patients or record use of corticosteroids. We did not measure parameters of global or regional perfusion that could help identify patients with increased risk of weaning levels during weaning in the noradrenaline patients totally dependent on the noradrenaline infusion at this time. Based on study protocol, we decided not to change the rate of vasoactive infusion or try suspending it. In spite of this, we showed that patients can be safely weaned while still using or refuted in a large prospective multicentre study, we believe that our data can be used to avoid unnecessary delays in the weaning process for patients taking noradrenaline.
